BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences in June.
Jefferies Healthcare Conference
Date: Friday, June 9, 2023
Time: 12:15 PM ET
Location: New York, NY
Goldman Sachs 44th Annual Global Healthcare Conference
Date: Wednesday, June 14, 2023
Time: 9:20 AM PT
Location: Dana Point, CA
A live webcast of the presentations will be available under the “Events & Presentations” tab on the “Investors” page on the Company’s website on the day of the event. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Amanda Galgay
SVP, Corporate Communications, Tango Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.33 |
Daily Change: | 0.38 12.88 |
Daily Volume: | 2,824,766 |
Market Cap: | US$356.780M |
November 06, 2024 November 06, 2024 August 07, 2024 June 05, 2024 May 08, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB